Journal of Medicinal Chemistry · 2023 · 23 citations · 17 references
MedicineMedicinal ChemistryPharmacologyChemotherapyDrug DiscoveryMolecular OncologyMicrotubule-associated ProteinsMicrotubule-targeting AgentsMolecular DockingCancer Cell ApoptosisCell Line-derived Xenograft ModelsDocking-based Pharmacophore DesignDual-target InhibitorsLigand-based Pharmacophore ScreeningMicrotubule Polymerization InhibitionPharmacophore-guided DockingTubulin Polymerization Inhibitors
Dual inhibition of tubulin and neuropilin-1 (NRP1) may become an effective method for cancer treatment by simultaneously killing tumor cells and inhibiting tumor angiogenesis. Herein, we identified dual tubulin/NRP1-targeting inhibitor TN-2, which exhibited good inhibitory activity against both tubulin polymerization (IC 50 = 0.71 ± 0.03 μM) and NRP1 (IC 50 = 0.85 ± 0.04 μM). Importantly, it significantly inhibited the viability of several human prostate tumor cell lines. Further mechanism studies indicated that TN-2 could inhibit tubulin polymerization and cause G2/M arrest, thereby inducing cell apoptosis. It could also suppress cell tube formation, migration, and invasion. Moreover, TN-2 showed obvious antitumor effects on the PC-3 cell-derived xenograft model with negligible side effects and good pharmacokinetic profiles. These data demonstrate that TN-2 could be a promising dual-target chemotherapeutic agent for the treatment of prostate cancer.
17
Recent Progress on Tubulin Inhibitors with Dual Targeting Capabilities for Cancer Therapy
Shuai Wen, Guan Wang, Yiwen Zhang et al. · Journal of Medicinal Chemistry · 2021 · 137 citations · Full text
Medicine, Oncology, Pharmacology +17